Medicine thermal insulation box with precise temperature control function, thermal insulation method and novel application of tetradecane

Abstract

The invention discloses a medicine thermal insulation box with a precise temperature control function, a medicine thermal insulation method, and a novel application of tetradecane. The medicine thermal insulation box with the precise temperature control function comprises a thermal insulation box body having a containing chamber, and an upper thermal insulation box cover which can be covered on the thermal insulation box body. The containing chamber is divided into a medicine containing chamber and a cold source containing chamber by a heat accumulation partitioning board. The heat accumulation partitioning board comprises a housing, and a heat accumulation agent which is sealed inside the housing and is of a phase-change temperature of 3-7 degrees centigrade. The medicine thermal insulation box with the precise temperature control function or the medicine anti-freezing thermal insulation method can utilize the heat energy of the heat accumulation agent to neutralize the cold energy of the cold source; in the process of delivering the heat energy, the heat accumulation agent can be solidified and discharge the heat energy when the temperature of the heat accumulation agent drops to the phase-change temperature, so as to further neutralize the cold energy of the cold source, thereby preventing the medicine from being frozen due to the excessively low temperature.

Description

technical field [0001] The present invention relates to the anti-freezing, cold storage and heat preservation during the transportation of refrigerated medicines, in particular to a refrigerated medicine incubator with precise temperature control used in the transportation of refrigerated medicines, a method for antifreeze and heat preservation of refrigerated medicines, and a new application of tetradecane, a medicine incubator with precise temperature control . Background technique [0002] In the hot season when the daily average temperature of 2-8°C refrigerated medicines in the prior art is higher than 8°C, the antifreeze incubators used for refrigerated transportation basically include a box body, and a refrigerated medicine holding chamber is arranged in the box body, and then the 2 ~ 8 ℃ refrigerated medicines and the cold source (ice box, ice bag, etc.) with a phase transition temperature of about 0 ℃ after freezing are placed in it, and the heat released by the col...

AI Technical Summary

Problems solved by technology

[0002] In the hot season when the daily average temperature of 2-8°C refrigerated medicines in the prior art is higher than 8°C, the antifreeze incubators used for refrigerated transportation basically include a box body, and a refrigerated medicine holding chamber is arranged in the box body, and then the 2 ~ 8 ℃ refrigerated medicines and the cold source (ice box, ice bag, etc.) with a phase transition temperature of about 0 ℃ after freezing are placed in it, and the heat released by the cold source balances the heat transferred to the medicine holding cavity by the cold source to achieve refrigeration Low-temperature storage of medicines with a temperature not higher than the upper limit of 8°C; this structure has the risk that the cold source will directly contact the refrigerated medicines, and cause the temperature of the medicines to be lower than the specified lower limit storage temperature of 2°C, which may damage the refrigerated medicines. Cannot meet the verification requirements of the new version of GSP: refrigerated medicines are strictly required to be accurately stored in cold storage at 2-8°C, neither higher than the upper limit temperature of 8°C nor lower than the specified lower limit temperature of 2°C, and the medicine box should not be in direct contact with the cold source

[0003] The improved method in the prior art is to place a partition between the cold source and the refrigerated medicine to prevent direct contact between the refrigerated medicine and the cold source, or to place the cold source in the slot on the inner wall of the incubator; although this method meets the requirements of the GSP drug The packing box should not be in direct contact with the cold source; however, because the supercooled cooling capacity of the cold source only delays its transfer speed, it has not been effectively and properly neutralized. After a long time, the supercooled cooling capacity will still be transferred to the refrigerator. In medicines, if the temperature of refrigerated medicines is 2°C lower than the lower limit storage temperature stipulated for medicines, there is a risk of freezing and damaging the refrigerated medicines, leading to the failure of medicines and causing medical safety accidents

[0004] The updated and improved method in the prior art is: place a partition between the cold source and the refrigerated medicine to prevent direct contact between the refrigerated medicine and the cold source, or place the cold source in the slot on the inner wall of the incubator; The supercooled cold source whose surface temperature is lower than 0°C is placed in an environment with a temperature higher than 2°C for more than 2 hours in advance to release the supercooled cooling energy so that the surface temperature is not lower than 0°C; although this method meets the GSP regulations Refrigerated medicines strictly require precise temperature control at 2-8°C, and also meet the regulations that refrigerated medicine packaging boxes should not be in direct contact with cold sources; however, there are the following obvious defects: the cold source that has been frozen must be refrigerated more than 2 hours in advance. Anti-overcooling release cooling operation, the operation process of this process is complicated, and the time required is too long to meet the requirements of modern cold chain logistics, which is ready-to-use, fast, and simple, and is not suitable for mass logistics operations; moreover, the cold source is supercooled. During the release process, about 30% of the cooling capacity of the cold source will be lost; in this way, in order to still meet the specified transportation cold storage time, it is necessary to increase the number of cold sources by about 30%, so the cold chain packaging box will inevitably lead to oversize and weight , greatly increasing the packaging and transportation costs of cold chain logistics by about 30%; therefore, on the surface, this approach fully meets the requirements of the new version of GSP on refrigerated drug transportation packaging, but in essence it is a helpless move that is not worth the candle

[0005] In the cold season when the daily average temperature of 2-8°C refrigerated medicines in the prior art is lower than 8°C, the antifreeze insulation boxes used for refrigerated transportation basically include a box body, and a refrigerated medicine storage chamber is arranged in the box body, and then the 2~8℃ refrigerated medicines and cold sources (ice boxes, ice packs, etc.) whose phase change temperature is around 0℃ and have not been frozen are put in, and the heat is released through the solidification process of the phase change energy storage material in the cold source from liquid to solid , to balance the cold energy transferred from the thermal environment to the drug containing cavity, and realize the refrigerated packaging of refrigerated drugs at 2-8°C; this structure has the problem that the cold source directly contacts with the refrigerated drug and cannot meet the new GSP regulations, and what is more serious is: Since the phase change temperature of the phase change energy storage material in the cold source is around 0°C, when the subcooling capacity of the outdoor environment is lower than 0°C, the phase change energy storage material of the cold source has a certain degree of supercooling, causing its The surface temperature is lower than 0 degrees Celsius (about -5 degrees Celsius), then, after the balance of the cold source of the environment is neutralized, the temperature is still lower than 0 degrees Celsius, and the supercooled coldness continues to be transferred to the medicine containing cavity, which will inevitably lead to The temperature of the drug is lower than 0°C, which will inevitably lead to the temperature of the drug being lower than the specified lower limit storage temperature of 2°C, which may cause the risk of freezing and damaging the refrigerated drug, and cannot meet the verification requirements of the new version of GSP: refrigerated drugs are strictly required to be accurately stored at 2-8°C. It can neither be higher than its upper limit temperature by 8°C nor lower than its specified lower limit temperature by 2°C, and the medicine box should not be in direct contact with the cold source

However, there is still no significant and effective solution to this problem in the prior art; therefore, it is basically an unrealistic dream to deliver and transport medicines stored in cold storage at 2-8°C to the northeast and other regions where the ambient temperature is too cold in winter. The production and sales manufacturers can only transport refrigerated medicines at 2-8°C in these cold regions in advance before the cold season, so as to avoid this transportation and packaging problem, that is, the so-called annual winter storage

Such operation can neither guarantee the timeliness of refrigerated drug transportation scheduling, but also greatly increase the storage cost of each refrigerated drug

Images